Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
03 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Global Anterior Uveitis Treatment Market (2020 to 2026) - Featuring Mylan, Allergan & Cadila Pharmaceuticals Among Others
22 févr. 2021 05h48 HE
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Anterior uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global anterior uveitis treatment...
Worldwide Uveitis Treatment Industry to 2026 - Key Motivators, Restraints and Opportunities
22 févr. 2021 05h43 HE
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global uveitis treatment market is projected...
Outlook on the Uveitis Treatment Global Market to 2025 - Impact of COVID-19 on the Market
18 déc. 2020 05h23 HE
|
Research and Markets
Dublin, Dec. 18, 2020 (GLOBE NEWSWIRE) -- The "Uveitis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development
01 août 2016 07h00 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...